|
Profile
|
Delegates :
Gaku Shimaoka, President |
|
Incorporated :
June 1 , 1997 |
Paid in Capital :
101 Million yen |
Employees :
19799 人 |
Address :
Roppongi Hills Mori Tower 6-10-1, Roppongi, Minatoku TOKYO
〒106-6135
|
TEL/FAX :
+81-3-6327-1082 / +81-3-6327-1083 |
URL：
https://www.technopro.com/en/ |
Attachment :
 Product_Profile_ENG_2023.pdf [ 1.5MiB ] |
Mission/Background :
TechnoPro R&D, an in-house company of TechnoPro, Inc., is a research solution company with numerous researchers who have obtained doctoral and master's degrees in the fields of biotechnology and chemistry.
We expand research services and staffing businesses, and provide technical capabilities supporting the advancement of technology.
Our own research centers have been established in six locations as research bases conducting biotechnology and chemistry, and performs research services to solve the technical challenges of our partners.
|
|
Technology & Business
|
[AI / iPSC-neuron research service]
Human iPSC neuron and artificial intelligence perform evaluation of neurotoxicity, pharmacology, efficacy of compounds utilizing cerebral cortex, dopaminergic, sensory and motor neurons co-cultured with astrocyte.
[Gene-related research service]
Preparation of gene expression vector, shRNA/siRNA, lentivirus plasmid and guide RNA/Cas9 expression plasmid,
[Protein engineering service]
Preparation with wheat germ cell-free, E coli, yeast, insect, and mammalian cells. The surface plasmon resonance for Intermolecular interaction
[Cell-related research services]
Mammalian and human primary cell cultures. Establishment of gene-transfected and gene-edited cells.
[Screening service]
Chemical compounds and proteins are screened in a cell-based or cell-free systems.
[Service workflow]
The single spot type, the milestone type and the FTE type for projects, followed by consultation, quotation, experiments and delivery results
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
AI / iPSC- neuron research
|
Service/Marketing
|
Based on extracellular action potential in iPSC neural network, compound screening, neurotoxicity, pharmacology, drug efficacy a
|
Service partners, collaborative research, Overseas marketing
|
Gene-related research
|
Service/Marketing
|
Gene expression vector preparation, shRNA/siRNA expression for gene knockdown, construction of plasmid for lentivirus preparatio
|
Service partners
|
Protein engineering
|
Service/Marketing
|
Protein preparation by expression systems of wheat germ cell-free synthesis, E coli, yeast, insect cell, and mammalian culture
|
Service partners, collaborative research
|
Cell-related research
|
Service/Marketing
|
Mammalian and human primary cell cultures. Establishment of gene-transfected and gene-edited cells.
|
Service partners
|
Screening
|
Service/Marketing
|
Chemical compounds and proteins are screened in a cell-based or cell-free systems.
|
Service partners
|
|
Highlights
|
[2023]
July 5-7\tExhibiting, PharmaLab Expo, the 25th Interphex Week Tokyo
March 7\t\tBusiness Alliance, Orizuru Therapeutics, Inc. (Human iPS cell technology)
Jan.23-Feb.13\tOral Presentation, Japan-UK Virtual Partnering
Jan. 11\t\tOral Presentation, Kansai Business Matching
[2022]
Oct. 11\t\tOral Presentation, EU-Japan Biotech & Pharma Partnering Conference 2022
Aug. 19\t\tCollaborative Research with the Institute for Protein Research, Osaka University
Feb. 1\t\tOpening, the Kyoto Research Center
|
|
Hot news
|
[Business Alliance]
The alliance regarding human iPS cell-related technology with Orizuru Therapeutics on March 7, 2023
[Essential publications in scientific journals from the university of the research alliance]
2023 : Large-Area Field Potential Imaging Having Single Neuron Resolution Using 236,880 Electrodes CMOS-MEA Technology
2022 : In Vitro Pain Assay Using Human iPSC-Derived Sensory Neurons and Microelectrode Array
|
|
Alliance strategy
|
We will form alliances of research service, collaborative research, and technology transfer on electrophysiology, neuroscience, gene/cell technology and protein engineering with academia, pharmaceuticals, nutrition and life science-related companies overseas and in domestic.
|
|
|